Recent success treating HCV and HIV is threatened by the rise of injection drug use (IDU) and the shifting demographics of people who inject drugs (PWID). As treatments become simpler, more effective, and more readily available, the responsibility to screen at-risk populations and manage patients to prevent and treat these dangerous infections has never been greater.
Join Kathleen Brady, MD, PhD, Alain Litwin, MD, and Sandra Springer, MD in a case based webinar to address ways that you can help fight against the surge in HCV and HIV. Topics include:
At the conclusion of each webinar, participants will have an opportunity to engage in a live Q&A session with our expert faculty.
This monograph was adapted from the live webinar HCV/HIV Virtual Roundtable: Treating HCV/HIV in People Who Inject Drugs. The learning objectives for this activity are:
Kathleen L. Brady, MD, PhD
Distinguished University Professor
Vice President for Research
Director, South Carolina Clinical and Translational Research Institute
Medical University of South Carolina
Alain Litwin, MD
Vice Chair of Academics and Research, Department of Medicine
Professor of Medicine, University of South Carolina School of Medicine Greenville
Professor, Clemson University School of Health Research
Sandra Springer, MD
Associate Professor of Medicine,
Department of Internal Medicine
Section of Infectious Disease
Yale School of Medicine
Dr. Sandra Springer is an associate professor of medicine in the Department of Internal Medicine, Section of Infectious Diseases at the Yale School of Medicine and the Infectious Disease physician at the VA Connecticut Healthcare System. She is triple board-certified in internal medicine, infectious diseases and addiction medicine. She has focused her clinical and research career on integrating substance use disorder and HIV treatment. In particular she has evaluated the use of medications for the treatment of opioid and alcohol use disorders among persons living with HIV involved in the criminal justice system to improve HIV viral suppression as well as reduce opioid and alcohol relapse post-release. She also was a working group member of NASEM’s historic meeting calling for action to integrate OUD and infectious disease treatment and currently appointed as NASEM committee member for ‘Examination of the Integration of Opioid and Infectious Disease Prevention Efforts in Select Programs’; and a current member of ASAM’s National Practice Guideline Expert PaneI for Medication Treatment for OUD; and current member of the IDSA and HIVMA Working Group on Infectious Disease Issues In the Opioid Epidemic. She has presented her work at numerous national and international conferences, and has published over 100 manuscripts, book chapters, and abstracts.
Jointly Provided by Postgraduate Institute for Medicine and DKBmed, LLC
This activity is supported by an independent educational grant from Gilead Sciences Inc.
This activity has been designed to meet the educational needs of healthcare professionals who treat patients with HCV, HIV, and injection drug use.
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and DKBmed, LLC. Postgraduate Institute for Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME).Credit Designation Statements
The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
After completing this activity, the participant should be better able to:
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:
The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:
The PIM planners and managers have nothing to disclose.
The following DKB planners and managers Stan Pogroszewski, Cade Schreger, and Rachel Deerr hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Participants wishing to earn credit must:
The estimated time to complete this activity is 1.0 hours.
Successful completion of the post-test is required to earn credit. Successful completion is defined as a cumulative score of at least 75%.
Internet Explorer 8.0+ for Windows 2000, 2003, XP, Vista, or Windows 7, 8, or 10
Google Chrome 18.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 13.0+ for Windows, Mac OS, or Linux
Safari 4.0+ for Mac OSX 10.5+